Table 1.
Characteristics of study population
| Older patients with anti-TNF therapy (n = 90) | Older patients without anti-TNF therapy (n = 145) | Younger patients with anti-TNF therapy (n = 257) | |
|---|---|---|---|
| Age at inclusion in years, median [IQR] | 68.72 [66.74–73.00] | 69.44 [65.01–75.02] | 37.43 [27.72–20.24]*** |
| Male, n (%) | 49 (54.4) | 84 (57.9) | 121 (47.1) |
| Age at diagnosis, mean (±SD) | 52.15 (16.10) | 46.39 (15.75)** | 26.16 (11.27)*** |
| Age at start anti-TNF therapy, mean (±SD) | 67.56 (6.00) | n.a. | 34.18 (12.94)*** |
| Disease duration in years, median [IQR] | 16.67 [5.73–29.48] | 21.31 [12.04–34.14]** | 10.14 [5.58–18.23]* |
| Duration of FU in weeks (start first anti-TNF till end FU or stop therapy) median [IQR] | 70.50 [34.00–155.25] | n.a. | 110.00 [41.50–217.00]* |
| Duration of FU in months (date diagnosis till malignancy or end FU), median [IQR] | 194.00 [66.00–322.50] | 249.00 [144.00–396.00] | n.a. |
| Duration of total anti-TNF therapy in years, median [IQR] | 1.72 [0.81–4.04] | n.a. | 3.34 [1.44–5.41]*** |
| Type of IBD, n (%) | |||
| CD | 56 (62.2) | 67 (46.2)** | 206 (80.2)** |
| UC | 30 (33.3) | 71 (49.0)** | 44 (17.1)** |
| IBD-U/IC | 4 (4.4) | 7 (4.8) | 7 (2.7) |
| Montreal classification, n (%) | |||
| CD location L1/L2/L3/L4 | 11 (19.6)/18 (32.1)/26 (46.2)/ 1 (1.8) | 14 (21.2)/25 (37.9)/27 (40.9)/0 (0.0) | 30 (14.6)/61 (29.6)/112 (54.4)/3 (1.5) |
| CD behaviour B1/B2/B3 | 19 (34.5)/26 (47.3)/10 (18.2) | 36 (53.7)/17 (25.4)/14 (20.9)* | 81 (39.5)/68 (33.2)/56 (27.3) |
| Perianal disease | 21 (41.1) | 10 (15.2)** | 85 (43.4) |
| UC extension E1/E2/E3 | 0 (0.0)/14 (45.2)/17 (54.8) | 2 (2.9)/29 (42.6)/37(54.4) | 1 (2.2)/12 (26.7)/32 (71.1) |
| Comorbidity, n (%) | |||
| Hepatic | 6 (6.7) | 14 (9.7) | 8 (3.1) |
| Gastrointestinal | 19 (21.1) | 28 (19.3) | 6 (2.3)*** |
| Cardiovascular | 35 (38.9) | 74 (51.0) | 34 (13.2)*** |
| Pulmonary | 10 (11.1) | 18 (12.4) | 18 (7.0) |
| Diabetes mellitus | 14 (15.7) | 18 (12.4) | 12 (4.7)** |
| Comorbidity, n (%) | |||
| No comorbidity | 35 (38.9) | 47 (32.4) | 191 (74.3)*** |
| One comorbidity | 33 (36.7) | 55 (37.9) | 54 (21.0) |
| Two or more comorbidities | 22 (24.4) | 43 (29.7) | 12 (4.7) |
| Type of TNF-inhibitor, n (%) | |||
| IFX | 67 | n.a. | 220* |
| ADA | 44 | 129 | |
| CZP | 0 (0.0) | 5 | |
| Immunosuppressant, n (%) | |||
| Thiopurines/MTX | 79 (87.8) | 51 (35.4)*** | 247 (96.1)** |
Older inflammatory bowel disease (IBD) patients (≥ 60 years) at initiation of anti-tumor necrosis factor (anti-TNF) therapy were compared with older IBD patients (≥ 60 years) without any anti-TNF therapy and with younger IBD patients aged < 60 years at initiation of anti-TNF therapy. Significant differences are shown. ***p < .001, **p < .01, *p < .05
IQR interquartile range, SD standard deviation, FU follow-up, CD Crohn’s disease, UC ulcerative colitis, IBD-U IBD unclassified, IC indeterminate colitis, IFX infliximab, ADA adalimumab, CZP certoluzimab pegol, MTX methotrexate
L4 was reported when only upper gastrointestinal (GI) disease was present, CD location was missing in N = 1 (group 3), CD behaviour was missing in N = 1 (group 1) and N = 1 (group 2), perianal disease was missing in N = 5 (group 1), N = 10 (group 2) and N = 1 (group 3), UC extension was missing in N = 3 (group 1), N = 6 (group 2) and N = 10 (group 3). The use of MTX was missing in N = 1 in the group with older IBD patients without anti-TNF therapy